Core Insights - Sanofi's brivekimig demonstrated positive results in the HS-OBTAIN phase 2a study for treating moderate-to-severe hidradenitis suppurativa (HS), showing clinically meaningful improvements in the primary endpoint of Hidradenitis Suppurativa Clinical Response (HiSCR50) [1][3][6] - The study indicated that brivekimig was well tolerated, with no serious adverse events reported [1][4] - The results will be presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress in Paris [1] Study Details - The HS-OBTAIN study was a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of brivekimig in biologic-naïve adults with moderate-to-severe HS [3][8] - Patients were randomized 2:1 to receive brivekimig 150 mg or placebo subcutaneously every two weeks for 16 weeks, followed by a 12-week open-label period and an 8-week safety follow-up [9] - The primary efficacy endpoint was the percentage of participants achieving HiSCR50 at week 16, with additional endpoints including HiSCR75, HiSCR90, and draining tunnel count [9] Efficacy Results - At week 16, 67% of patients in the brivekimig group achieved HiSCR50 compared to 37% in the placebo group, with a probability of superiority of 99.28% [7] - For HiSCR75, 54% of patients treated with brivekimig achieved this endpoint versus 22% with placebo [7] - HiSCR90 was achieved by 31% of patients in the brivekimig group compared to 9% in the placebo group [7] - The mean percent change from baseline in draining tunnel count was -56.0% for brivekimig versus +10.9% for placebo [7] Company Commitment - Sanofi emphasizes its commitment to addressing underlying inflammation in chronic inflammatory skin diseases through innovative treatments like brivekimig [5][6] - The company is exploring brivekimig's potential across a range of immune-mediated diseases [6][10]

- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARIâ"¢ for the treatment of moderate-to-severe acne - SAN DIEGO, CA / ACCESS Newswire / September 17, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced the presentation of an abstract from its XYNGARIâ"¢ (also known as DMT310) Phase 3 Spongilla Treatment of Acne Research clinical trial (STAR-1) will ...

Nothing that the Trump administration is doing to the Fed will make it any more difficult for the profit machines that power the stock market to earn cash. ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Informatica, a leader in enterprise AI-powered cloud data management, is proud to announce its latest round of recognition. Honored as one of TIME's America's Best Mid-Size Companies 2025, Named among Europe's Best Employers for 2025 by the Financial Times. These prestigious honors—presented in partnership with Statista—are a testament to Informatica's sustained commitment to employee satisfaction, responsible growth and sustainable business practices, and. ...

TSXV: PGZÂ |Â OTCQB: PGZFFÂ |Â FRA: 2EU Roger Davey served as Chairman, Atalaya Mining, for a decade supporting the refurbishment, commissioning, and re-start of mining operations at the Riotinto Mine in Spain VANCOUVER, BC , Sept. 17, 2025 /PRNewswire/ - Pan Global Resources Inc. ("Pan Global" or the "Company") (TSXV: PGZ) (OTCQB: PGZFF) (FRA: 2EU) is pleased to announce the appointment of UK-based mining executive Roger Davey to the Company's Board of Directors (the "Board"). ...

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EADV25--Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025. ...

SHENZHEN, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Notified, the leading communication technology partner for investor relations (IR) and public relations (PR) professionals, is co-hosting an exclusive IR forum with Futu, featuring Nasdaq as a special guest on Wednesday, 17 September, 2025 in Shenzhen, China. The event brings together executives from China, Hong Kong and U.S.-listed companies to explore the latest IR trends and breakthrough strategies for engaging international institutional and retail investors ...

Nissan Motor is studying the cost competitiveness of Chinese suppliers and exploring ways to apply their practices globally, as it aims to cut variable costs by 250 billion yen ($1.71 billion) in a br... ...

A Wells Fargo banker, Chenyue Mao, who had been barred from leaving China for several months, has been allowed to return to the United States following negotiations between U.S. and Chinese officials, according to two people with knowledge of the case. ...

Benchmark equity indices Sensex and Nifty rallied in initial trade on Wednesday following positive day-long discussions with the visiting US team on a bilateral trade deal with both sides agreeing to push for an early and mutually beneficial conclusion of the agreement.The 30-share BSE Sensex rallied 262.74 points to 82,643.43 in early trade. The 50-share NSE Nifty climbed 85.25 points to 25,324.35.From the Sensex firms, Bharat Electronics, UltraTech Cement, Trent, Larsen & Toubro, Tata Consultancy Serv ...